Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Roluperidone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Minerva Neurosciences Launches Global Phase 3 Roluperidone Trial
    Minerva Neurosciences Launches Global Phase 3 Roluperidone Trial

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3266016/32445/en/Minerva-Neurosciences-Announces-First-Patient-Screened-in-Global-Phase-3-Confirmatory-Trial-of-Roluperidone-for-the-Treatment-of-Negative-Symptoms-of-Schizophrenia.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    Minerva Neurosciences Reveals Roluperidone-Olanzapine Safety
    Minerva Neurosciences Reveals Roluperidone-Olanzapine Safety

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262573/32445/en/Minerva-Neurosciences-Presents-Data-from-its-Open-label-Safety-Trial-Evaluating-Roluperidone-Co-administered-with-Olanzapine-at-SIRS-2026.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    Minerva Neurosciences Hosts Virtual KOL Event On Roluperidone
    Minerva Neurosciences Hosts Virtual KOL Event On Roluperidone

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225490/32445/en/Minerva-Neurosciences-to-Host-Virtual-KOL-Event-to-Discuss-Roluperidone-From-Unmet-Need-to-Reality-Potentially-the-First-Treatment-for-Patients-with-Negative-Symptoms-of-Schizophre.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    Minerva Neurosciences Secures $200M To Advance Roluperidone
    Minerva Neurosciences Secures $200M To Advance Roluperidone

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3170126/32445/en/Minerva-Neurosciences-Announces-Financing-of-up-to-200-Million-to-Advance-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia-Through-a-Phase-3-Confi.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Minerva Neurosciences Updates Business, Reports Q2 Financial
    Minerva Neurosciences Updates Business, Reports Q2 Financial

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133933/32445/en/Minerva-Neurosciences-Provides-Business-Updates-and-Second-Quarter-Financial-Results.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share
    Minerva's schizophrenia drug rejected by FDA for 2nd time
    Minerva's schizophrenia drug rejected by FDA for 2nd time

    28 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time

    FIERCE BIOTECH
    28 Feb 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.